Two samples were received for investigation on 28-mar-2024.The samples were tested on a cobas e 801 and a cobas pro with cir retention kits.Investigation results: sample 1: the anti-hbs ii result was 44.4 iu/l.The anti-hbc ii result was 0.00707 coi reactive.The hbsag ii result was 9.16 coi reactive.Sample 2: the anti-hbs ii result was 45.3 iu/l.The anti-hbc ii result was 0.00714 coi reactive.The hbsag ii result was 9.42 coi reactive.The positive anti-hbs ii result was reproduced during the investigation.Therefore, the positive anti-hbs ii result is assumed to be unspecific/false positive.A (lot independent) interference is most likely.Product labeling states: "individuals that have received blood component therapy, e.G.Whole blood, plasma, immune globulin administration, during the previous 3 to 6 months may have a false reactive anti-hbs result due to passive transfer of anti-hbs." the reagent performed within specification.The investigation did not identify a product problem.
|